Abstract
Objective:
The aim of the study was to evaluate therapeutic effects and tolerability of fluvoxamine (150–200 mg daily) in 21 dysthymic adolescents.
Subjects:
Twenty-one adolescents, attending psychiatric clinics, who met DSM-III-R criteria for dysthymia, without significant co-morbidity were the subjects.
Methods:
Results:
Good clinical response (decrease of HAMD-S score >50%) was observed after 4 weeks in 48% of patients; after 8 weeks in 56% of patients, and after 26 weeks in 44% patients. Relapse occurred in 34% of subjects. Fluvoxamine was well tolerated in 76.2% of the adolescents; poor toleration resulted in its discontinuation in 14.2% adolescents.
Get full access to this article
View all access options for this article.